March 2013. The U.S. Food and Drug Administration (FDA) has determined that tolvaptan should not be used for longer than 30 days and should not be used in patients with underlying liver disease because it can cause liver injury, potentially requiring liver transplant or death.
- TRADE NAME: Samsca (Otsuka)
- INDICATIONS: Chronic heart failure, hyponatremia, polycystic kidneys
- CLASS: Vasopressin receptor antagonist
- HALF-LIFE: 6–8 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aprepitant, Barbiturates, Benazepril, Captopril, Carbamazepine, Clarithromycin, Conivaptan, Cyclosporine, Darunavir, Delavirdine, Digoxin, Efavirenz, Enalapril, Fosinopril, Grapefruit Juice, Indinavir, Irbesartan, Itraconazole, Ketoconazole, Lapatinib, Lisinopril, Lovastatin, Miconazole, Nefazodone, Nelfinavir, Olmesartan, Oxcarbazepine, P-gp inhibitors, Phenytoin, Quinapril, Ramipril, Rifabutin, Rifampin, Rifapentin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Strong CYP3A inhibitors, Telithromycin, Voriconazole
INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
